Genesiscare, Research Report 2025 – leading the way in research
Biomarker-oncology is leading the way in personalised cancer treatment
The GenesisCare Research Report 2025 is out and full of some amazing accomplishments that the national teams have achieved. Across our 52 centres, research and clinical trials have been paving the way in patient-centred cancer treatments. We had a productive and very busy year!
Biomarker-driven oncology now underpins modern cancer care. Almost half of all oncology clinical trials incorporate biomarkers, reflecting a shift from traditional organ-based treatment approaches toward molecularly targeted therapies. Increasingly, trials assess multiple biomarkers simultaneously — sometimes including multiple tumour markers — allowing treatment decisions to be guided by tumour biology rather than anatomical site alone.
This evolution is reflected at GenesisCare, where more than 80% of coordinated oncology clinical trials now involve molecularly targeted therapies, aligning with the organisation’s patient-centred approach to care.
“We are so proud of the work we do in research and clinical trials. 2025 was a busy year with some groundbreaking advances in theranostics and radiation oncology and many world-firsts” – Sonya McColl, Head of Research, GenesisCare Australia
Proud to be the first!
- First site globally to offer ProstACT GLOBAL – a theranostics study for prostate cancer
- First to administer 177Lu-RAD202 – a theranostics study for breast cancer
- First patient in the world recruited for 3BP NTA476 177Lu – a theranostics study for prostate cancer
- First patient in APAC for Beigene haematology – an innovative haematology therapy for B-cell malignancies
- First to globally deliver prostate SABR treatment via a sim-less workflow on MR Linac – improving treatment efficiencies and shortening patient treatment time
Across our network we had 217 sites (inc. multisite studies) nationally, encompassing interventional and observational research across medical oncology, haematology, radiation oncology, and theranostics. In addition, we contributed to initiatives and clinical quality registries and produced 62 peer-reviewed publications.
“Our continued efforts in building strategic partnerships including Harry Perkins Medical Research, UNSW, Edith Cowan Uni and many local health districts, shows our commitment to innovation and excellence in cancer care.” Dr Marcus Dreosti, Chief Medical Officer, Radiation Oncologist.
Read the full resarch report
Discover the highlights from the GenesisCare Research Report 2025, including advances in biomarker-driven oncology, theranostics and world-first clinical trials.
2025 was a busy year with some ground-breaking work in theranostics and radiation oncology and, many world-firsts.
- Sonya McColl, Head of Research, GenesisCare Australia
